The global Liver Cancer Therapeutics Market size is forecasted to grow USD 1148 million by 2026 from USD 743 million in 2021, registering a CAGR of 9.1% during the forecast period.
Liver cancer signifies the fifth most generally arising cancer and the third foremost reason for deaths associated with cancer globally. Hence, the liver cancer diagnosis and medication market are projected to become an active ground for competition in the coming few years. Several new-targeted therapies are predicted to arrive in the Liver Cancer Therapeutics Market shortly.
Directed cancer therapies practice medication to avoid the growth of cancer cells by intruding certain molecules, known as molecular targets, thus preventing the movement and development of cancer cells. The treatment procedures mainly focus on the cellular and molecular variations, affecting precisely cancer cells.
MARKET DRIVERS:
The growing aging population, unmet requirements for liver cancer treatment, drug inventions concerning cancer, increasing government initiatives, rising cancer occurrences, and mounting health care expenditure are majorly accelerating the global liver cancer therapeutics market.
According to Globocan, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous diseases have developed in the launch of new drugs, rising FDA approvals for the treatment of hepatocellular carcinoma accounting for 90% of liver cancer. Factors such as alcohol consumption, smoking, and increasing urbanization reasons for liver cancer majorly lead to liver cancer. The rising support from governments and investments made by the international healthcare organizations positively reflect the global liver cancer therapeutics market. A wide range of treatment options available for liver cancer may uplift the demand levels in the near future.
MARKET RESTRAINTS:
However, factors such as stringent regulatory processes, high capital investments, the low success rate in clinical trials for drugs, and low approachability in remote areas hinder the growth of the global liver cancer therapeutics market.
Impact of COVID-19 on the global liver cancer therapeutics market:
The COVID-19 has created an adverse impact on the liver cancer therapeutics market. The pharmaceutical companies are adopting plans to maintain the balance between the supply chain and demand, increasing the products' sales regarding the COVID 19 emergency. Healthcare organizations have imposed strict guidelines for the management of hepatocellular carcinoma patients amid the COVID 19 crisis. The studies have stated that patients with HCC are at high risk of contracting the infection. Therefore, patients are considered in the emergency category during the crisis period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Type, Therapeutics, End Users, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company. |
This research report on the global liver cancer therapeutics market has been segmented and sub-segmented based on type, therapeutics, end-users, and region.
Liver Cancer Therapeutics Market - By Type:
Based on the type, the secondary type had dominated the market in 2019 and is estimated to continue the dominating trend during the forecast period. Secondary liver cancer is also known as metastatic liver cancer.
Liver Cancer Therapeutics Market - By Therapeutics:
Based on therapeutics, the Hepatocellular Carcinoma segment is the largest therapeutics type due to its high prevalence of liver cancer. According to the National Organization for Rare Diseases (NORD), there are nearly six new cases of HCC per every 100,000 people in the general population of the U.S. In addition, the high occurrence of cancer and high unemployed medical needs drives the market growth during the analysis period.
The targeted therapy is expected to grow at the highest pace. The segment mainly involves tyrosine inhibitors, limiting the several kinase proteins that accelerate cancer cell growth.
Liver Cancer Therapeutics Market - By End-Users:
The adult end-user segment is expected to lead the global liver cancer therapeutics market during the forecast period due to high alcohol consumption and tobacco intake.
Liver Cancer Therapeutics Market - By Region:
Geographically, North America is the largest market for liver cancer therapeutics, followed by Europe and Asia. The growth of the North American market is majorly driven by the factors such as the appearance of better healthcare infrastructure and increasing aged population. The United States is leading the North American market due to the Y-O-Y increase in liver cancer cases and the growing demand for liver cancer treatment. As per the American Society of Clinical Oncology, around 42,220 adults are diagnosed with liver cancer in the U.S. as of 2018. In addition, the early adoption of advanced technology diagnosis products and liver cancer methods makes the region grow more robust. The Canadian liver cancer therapeutics market is next to the U.S. in leading the market. The market players focus more on research and development activities to develop new treatments for liver cancer treatment.
The European market was the second-largest regional market in the global market in 2019. The growth of the European market is mainly growing due to rising investments in the research and development of effective therapeutic drugs. Moreover, the targeted drug therapy products lead the market forward. U.K. and Germany are leading economies of the European market. The U.K. is leading the market and is to dominate throughout the forecast period. According to the Cancer Research Organization, around 5,736 liver cancer cases were reported in the U.K. in 2015. The liver cancer therapeutics market in Germany and France is observed to grow at the highest CAGR pace. The acquisition of advanced diagnostic tools and high-volume pharmaceutical and biotechnology companies augment the market demand.
Also, Asia-Pacific signifies the fastest-growing region for the liver cancer therapeutics market, owing to increasing aged populations. In addition, an increasing number of liver cancer cases in Asian countries is further fuelling the market in this region. The rising number of clinical studies regarding liver disease, including cancer and rising older adults, is another significant factor contributing to the growth of the APAC market. China is a promising destination for market players in the industry. The broad base target population and vital unused medical needs support the major push to the market growth.
On the other hand, Latin America and the Middle East & Africa are likely to witness considerable market growth in liver cancer therapeutics. Increasing funds and investments by both public and private organizations in research and development in treating cancer.
KEY MARKET PARTICIPANTS:
Some of the significant contributors in the global liver cancer therapeutics market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Primary
5.1.2 Secondary
5.1.3 Benign Liver growths
5.2 By Therapeutics
5.2.1 Hepatocellular Carcinoma
5.2.2 Cholangio carcinoma
5.2.3 Hepatoblastoma
5.2.4 Targeted Therapy
5.3 By End-Users
5.3.1 Pediatrics
5.3.2 Adults
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Alnylam Pharmaceuticals Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 ImClone Systems Inc.
9.3 Onyx Pharmaceuticals Inc.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Pfizer Inc.
9.6 ArQule Inc.
9.7 Jennerex Biotherapeutics Inc.
9.8 Celsion Corp.
9.9 Bayer Schering Pharma AG
9.10 4SC AG
9.11 Bristol-Myers Squibb Company
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
